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Improved Gastrointestinal Symptoms and Quality of Life after 
Conversion from Mycophenolate Mofetil to Enteric-Coated 
Mycophenolate Sodium in Renal Transplant Patients Receiving 
Tacrolimus
It is reported that a conversion from mycophenolate mofetil (MMF) to enteric-coated 
mycophenolate sodium (EC-MPS) relieves gastrointestinal (GI) symptom burden and 
improves health-related quality of life (HRQoL). However, it is unclear whether renal 
transplant recipients using tacrolimus receive the same benefit from the conversion. In this 
prospective, multi-center, open-label trial, patients were categorized into two groups by 
their GI symptom screening. Equimolar EC-MPS (n=175) was prescribed for patients with 
GI burdens; those with no complaints remained on MMF (n=83). Gastrointestinal 
Symptom Rating Scale (GSRS) and Gastrointestinal Quality of Life Index (GIQLI) were 
evaluated at baseline and after one month. Patients and physicians completed Overall 
Treatment Effect (OTE) at one month. EC-MPS-converted patients had worse GSRS and 
GIQLI scores at baseline than MMF-continued patients (all P<0.001). Significant 
improvements in GSRS and GIQLI scores were observed for EC-MPS-converted patients at 
one month, but MMF-continued patients showed worsened GSRS scores (all P<0.05). OTE 
scale indicated that EC-MPS patients improved in overall GI symptoms and HRQoL more 
than MMF patients did (P<0.001). In tacrolimus-treated renal transplant recipients with GI 
burdens, a conversion from MMF to EC-MPS improves GI-related symptoms and HRQoL.
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INTRODUCTION
Mycophenolate mofetil (MMF) is one of the most successful 
medications used in renal transplantation, showing reduction 
in acute rejection and late allograft loss (1-3). However, gastro-
intestinal (GI) side effects are common, and inadequate myco-
phenolic acid (MPA) exposure can limit its clinical benefits (4). 
Enteric-coated mycophenolate sodium (EC-MPS) has been de-
veloped to improve GI tolerability of MPA treatment. Conver-
sion from MMF to EC-MPS can be safely undertaken without 
compromising efficacy de novo and maintenance of renal trans-
plant recipients (5, 6). 
  GI symptoms and subsequently impaired quality of life is 
prevalent among renal transplant recipients (7). It was previ-
ously demonstrated that a conversion from MMF to EC-MPS 
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life (HRQoL) in a study using patient-reported outcomes mea-
sures (8, 9). However, such benefits obtained from converting 
to EC-MPS is not easily applicable in patients receiving tacroli-
mus; since MPA therapy provides pharmacokinetic interaction 
with tacrolimus, MPA exposure would be augmented in combi-
nation with tacrolimus (10-12). Furthermore, tacrolimus has its 
own inherent GI side effects (7, 13). Thus, patients who receive 
MPA therapy and tacrolimus simultaneously can experience 
more severe GI disorders and impaired HRQoL.
  Based on these findings, the present study was undertaken 
with renal transplant recipients receiving tacrolimus to investi-
gate the impact of conversion from MMF to EC-MPS. The aim 
of this study was to determine whether patients with GI com-
plaints can experience improvement on symptom severity and 
GI-specific HRQoL after converting to EC-MPS. The impact of 
EC-MPS conversion on general HRQoL was also investigated; 
the result was then compared with that of patients without GI 
complaints who remained under MMF.
MATERIALS AND METHODS
Study design and conduct
This study consisted of multicenter, longitudinal, open-label, 
and prospective trials in adult renal transplant patients receiv-
ing MMF (CellCept, Roche) in combination with tacrolimus. 
Patients were recruited at seven transplant centers (Seoul St. 
Mary’s hospital, Samsung Seoul Medical Center, Seoul National 
University hospital, Bong Seng Memorial hospital, Busan Paik 
hospital, Kyungpook National University hospital and Ajou Uni-
versity Medical Center) in Korea. All patients completed a sim-
ple questionnaire that classified them into EC-MPS (Myfortic, 
Novartis Pharmaceuticals Corporation)-converted or MMF-con-
tinued group, and patient-reported outcomes measures were 
evaluated at baseline and one month (Fig. 1). 
Study population
Patients aged 18-65 yr were eligible to enter the study if they had 
received a renal transplant at least three months prior to the re-
search and had been receiving a combination of MMF and tacro-
limus with or without corticosteroids for at least two weeks at 
the time of study entry. Patients were ineligible to enter the study 
if they were experiencing GI symptoms that were not known or 
assumed to be caused by MMF, had experienced an episode of 
acute rejection, or were undergoing acute medical illness with-
in two weeks prior to study entry. Patients were also excluded if 
they satisfied following criteria: multiorgan recipients; positive 
T-cell crossmatch; ABO incompatibility against donor; serum 
creatinine >2.0 mg/dL at screening or baseline; leukopenia (<2,500 
cells/µL) and/or absolute neutrophil count of <1,500 cells/µL; 
thrombocytopenia (<75,000 cells/µL); hepatitis B or C virus in-
fection. 
Simple questionnaire for patient grouping
At study entry, all patients completed a simple questionnaire 
for whether they had experienced GI symptoms during previ-
ous three months. This questionnaire has six subscales (indiges-
tion, bloating, upper abdominal pain, nausea, vomiting and di-
arrhea) that have a six-point graded Likert-type scale, where 0 
represents no discomfort and 5 represents continual discom-
fort. For patients with total subscale scores above or equal to 2, 
prescriptions were converted from MMF to EC-MPS (EC-MPS-
converted group). Patients with total subscale scores below 2 
remained on MMF medication (MMF continued group).
Immunosuppression
Patients in EC-MPS-converted group were converted from MMF 
to an equimolar dose of EC-MPS at baseline; EC-MPS doses of 
360 mg, 720 mg, 1,080 mg, and 1,440 mg corresponded to MMF 
500 mg, 1,000 mg, 1,500 mg, and 2,000 mg, respectively. Dose 
reduction or temporary interruption of EC-MPS or MMF was 
permitted in cases of leukopenia (<4,500 cells/µL), neutropenia 
(<1,500 cells/µL), thrombocytopenia (<75,000 cells/µL), or in 
response to moderate or severe adverse events. Discontinuation 
of EC-MPs or MMF was considered if it was interrupted for lon-
ger than 10 days. Tacrolimus with or without corticosteroids was 
administered according to the participating center protocols.
Patient-reported assessment
Two self-administered questionnaires were used (14). The Gas-
trointestinal Symptom Rating Scale (GSRS) is a 15-item instru-
ment designed to assess common GI symptoms. It has five sub-
Total study population  
(N=276)
Simple questionnaire for GI symptoms
  Visit 1  GSRS, GIQLI
  Visit 2 (4 weeks)  GSRS, GIQLI, OTE
EC-MPS converted  
group (n=188)
Total scores ≥2
MMF continued  
group (n=88)
Total scores <2
Fig. 1. Schematic diagram of study design and conduct. 
EC-MPS, enteric-coated mycophenolate sodium; MMF, mycophenolate mofetil; GSRS, 
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scales (reflux, diarrhea, constipation, indigestion, and abdomi-
nal pain) with subscale scores ranging from 1 (no discomfort) 
to 7 (severe discomfort). Higher scores represent higher symp-
tom burden. The Gastrointestinal Quality of Life Index (GIQLI) 
is a 36-item GI-specific HRQoL instrument designed to assess 
the quality of life in patients with GI disorders. It has five sub-
scales (GI symptoms, social function, physical function, emo-
tional status, and use of medical treatment) and a total of 36 
items, with a total score ranging from 0 to 144. Higher scores 
mean better GI specific HRQoL. Patients completed GSRS and 
GIQLI questionnaires at each study visit. 
  The effect of the treatment in terms of HRQoL changes was 
investigated at end of one month, using the Overall Treatment 
Effect (OTE) scale. The first question asks whether general HRQoL 
has improved, remained the same, or deteriorated. Respondents 
who indicated improvement or deterioration were further asked 
to identify the extent of the change on the 7-point scale, with 1 
being almost the same and 7 being great deal better or worse. 
In addition, physicians also completed the OTE questionnaire 
for symptom assessment at the end of one month.
Study endpoints
The primary efficacy variable was the change in overall GSRS 
score from the baseline within one month in EC-MPS-convert-
ed patients. Secondary efficacy variables included the change 
in GIQLI from the baseline within one month, the change from 
baseline in GSRS and GIQLI subscale scores, and the OTE scores 
by patients and physicians. Safety variables included the occur-
rence of adverse events, serious or severe adverse events, medi-
cation stop, acute rejection, graft loss, and death.
Statistical analysis
Efficacy analyses were performed on per-protocol population, 
which is defined as all patients who completed the study with 
no protocol violations. Safety analyses were performed on ITT/
safety population, which consisted of all patients who received 
at least one dose of EC-MPS or MMF. Patient-reported outcomes 
results are reported as mean±SD. Baseline, one month scores, 
and changed scores in GSRS and GIQLI overall and all subscales 
was compared using Student t test between EC-MPS converted 
and MMF continued groups. Changes in GSRS and GIQLI over-
all and subscale scores within groups were tested using a paired 
t test. Fisher’s exact test or chi-square test was used for categori-
cal variables. All statistical tests used were two-sided with a sig-
nificance level of 0.05.
Ethics statement
The study was approved by the Institutional Review Board of 
Seoul St. Mary’s hospital (KCMC08MI197). Written informed 
consent was obtained from all study patients. 
RESULTS
Study population at baseline
A total of 276 patients who enrolled (188 in EC-MPS-converted 
group and 88 in MMF-continued group) comprised the ITT/
safety population. Among them, thirteen patients (6.9%) in EC-
MPS-converted group and five patients (5.7%) in MMF-contin-
ued group discontinued prematurely (11, administrative prob-
lems; 3, adverse events; 3, subject withdrew consent; 1, death). 
The per-protocol population consisted of 258 patients--175 in 
EC-MPS-converted group and 83 in MMF-continued group.
  Table 1 describes the baseline patient demographics. Patients 
in EC-MPS-converted group had a greater prevalence of young-
er, taller and female patients. The daily MMF doses before con-
version were not different between two groups. When patients 
were grouped based on simple questionnaire scores, EC-MPS-
converted group had a significantly higher mean score than 
MMF continued group (6.85±4.02 vs 0.40±0.49; P<0.001; Fig. 2). 
All subscale scores for the simple questionnaire were also differ-
ent, and most pronounced distinctions in the symptoms were 
bloating and upper abdominal pain.
Patient-reported outcomes at baseline
The overall GSRS score at the baseline was 2.46±0.81 in EC-MPS-
Table 1. Baseline demographic characteristics
Variables
   EC-MPS  
   (n=188)
    MMF  
    (n=88)
P
Age (yr)     43.8±10.0     46.6±11.4 0.042 
Male (%)   101 (53.7%)    64 (72.7%)  0.003 
Height (cm) 164±9 167±8 0.014
Weight (kg)     63±15   63±9 0.911
Time since transplant (yr)     3.5±3.3     3.7±3.3 0.700
Donor type
   Living (%)
   Deceased (%)
  127 (68.1%)
    60 (31.9%)
   63 (71.6%)
   25 (28.4%)
0.732
HLA mismatch number   1.64±3.2   1.54±3.4 0.357
MMF dose before conversion (g/day)     1.20±0.37     1.19±0.35 0.741
EC-MPS, enteric-coated mycophenolate sodium; MMF, mycophenolate mofetil.
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Fig. 2. Simple questionnaire screening for GI symptoms. *denotes P values <0.001. 
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converted group and 1.54±0.51 in MMF continued group (Fig. 3). 
This difference indicates a significantly worse symptom burden 
in EC-MPS-converted group (P<0.001). EC-MPS-converted 
group also had significantly higher scores on all GSRS subscales 
and lower scores on GIQLI overall and subscale scores than MMF 
continued group (all P<0.001). The overall GIQLI score was 2.94 
±0.48 for EC-MPS-converted group and 3.35±0.34 for MMF con-
tinued group. 
Changes in patient-reported outcomes
The overall GSRS score after one month was 2.11±0.74 in EC-
MPS-converted group, which was significantly lower than the 
baseline score (P<0.001). All GSRS subscale scores except con-
stipation were improved in EC-MPS-converted group (P=0.426 
for constipation and all P<0.05 for other subscales). On the oth-
er hand, overall GSRS score in MMF continued group increased 
after one month (1.54±0.51 at baseline vs 1.71±0.64 at one month; 
P=0.002), and all subscales scores except diarrhea deteriorated 
(P=0.271 for diarrhea and all P<0.05 for other subscales). When 
the changed GSRS scores between two groups were compared, 
the overall GSRS score was significantly reduced in EC-MPS-
converted group (Fig. 4A), and the difference remained signifi-
cant even after the scores were adjusted for age, sex, height and 
investigation centers (P<0.001). The changed scores in all GSRS 
subscales were also different between two groups, with the great-
est change reported in abdominal pain subscale (all P<0.05).
  Significant improvement after one month was observed for 
GIQLI overall and all subscale scores in EC-MPS-converted group 
(all P<0.05). The overall GIQLI score after one month was 3.11± 
0.41, with the greatest change reported in GI symptom subscale 
(P<0.001). In MMF continued group, overall GIQLI (3.35±0.34 
at baseline vs 3.30±0.39 at one month; P=0.085) and some sub-
scale scores after one month remained stable, or even decreased 
in GI symptoms and medical treatment subscale (P=0.031 and 
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Fig. 3. Patient-reported outcomes at baseline in EC-MPS converted and MMF continued group. (A) GSRS subscale scores (B) GIQLI subscale scores. 
*denotes P values <0.001. Note the significantly impaired GSRS and GIQLI all subscale scores in EC-MPS converted group. 
EC-MPS, enteric-coated mycophenolate sodium; MMF, mycophenolate mofetil; GSRS, Gastrointestinal Symptom Rating Scale; GIQLI, Gastrointestinal Quality of Life Index.
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A B
*
*Hwang HS, et al.  •  MMF and EC-MPS in Tacrolimus-treated Renal Transplant Recipients
http://jkms.org   1763 DOI: 10.3346/jkms.2010.25.12.1759
P=0.012, respectively). In comparison to MMF continued group, 
EC-MPS-converted group had significantly different changes in 
GIQLI overall and subscale scores, even after adjusting the scores 
for demographic and clinical characteristics (P<0.05) (Fig. 4B). 
Overall treatment effect
Patient-rated OTE after one month showed that 70 patients 
(40.0%) in EC-MPS-converted group made an improvement in 
their HRQoL in comparison to the baseline, while only seven 
patients (8.4%) in MMF-continued group reported such an im-
provement (Fig. 5). For physician-rated OTE, GI symptom im-
proved, remaining unchanged, or worsened in 79 patients (45.1 
%), 82 patients (46.1%) and 14 patients (8.9%) in EC-MPS-con-
verted group, respectively. In MMF continued group, two (2.4%), 
73 (88.0%), and eight patients (9.6%) displayed such a pattern. 
Thus, distributions for patient and physician-rated OTE were 
significantly different between two groups (all P<0.001).
 
Safety
A total of 38 GI adverse events were developed, which indicated 
no significant difference between EC-MPS-converted and MMF-
continued groups (14.4% vs 12.5%; P<0.676). Of these events, 
the percentage of severe adverse events (2.1% vs 0%; P=0.310), 
adverse events related to study drug (10.1% vs 5.7%; P=0.260), 
and events that required further treatment (9.0% vs 8.0%; P= 
0.765) were not significantly different between EC-MPS and 
MMF converted group. Diarrhea was the most frequently-oc-
curring GI complaint with nine incidents reported (4.8%) in EC-
MPS-converted group and one event (1.1%) in MMF continued 
group (P=0.177). The five patients (2.7%) who discontinued 
medication for GI adverse events were present in only EC-MPS-
converted group, but their percentage in comparison to the to-
tal number of participants in EC-MPS-converted group was not 
significantly different from that of MMF continued group (P= 
0.181).
  Seventy-six non-GI adverse events were present in study pop-
ulation. The frequency of non-GI adverse events in EC-MPS-
converted group was significantly higher compared to that of 
MMF continued group (33.5% vs 14.8%; P=0.001). Common 
cold was the most common non-GI adverse event, reported in 
seventeen times (9.0%) in EC-EMP-converted group and two 
(2.3%) times in MMF continued group (P=0.042). The incidence 
of non-GI adverse events with a suspected relation to study drug 
was not significantly different between two test groups (EC-MPS 
3.2% vs MMF 1.1%; P=0.437). In EC-MPS-converted group, four 
patients (all, infection) experienced non-GI serious adverse 
events. Four patients (2, infection; 2, nervous system disorders) 
discontinued EC-MPS permanently due to non-GI adverse 
events. In MMF continued group, no patient experienced seri-
ous adverse event or discontinued the prescription. In that re-
gard, the incidences of serious adverse events and discontinu-
ance of medication were not statistically different between two 
groups (all P=0.310). Two patients died from cerebral aspergil-
losis and pneumonia in EC-MPS converted group, but no epi-
sodes of acute rejection and graft loss were reported in patients 
of both groups. 
DISCUSSION
With a increasing success in renal grafts and a decrease in pa-
tient mortality, there is a growing need to optimize immuno-
suppressants for improving HRQoL in renal transplant patients. 
This study demonstrates that a conversion from MMF to EC-
MPS was effective in improving GI symptom and HRQoL in re-
nal transplant recipients receiving tacrolimus. Significant im-
provements were consistently observed for GSRS and GIQLI 
scales, even though all of EC-MPS-converted patients already 
expressed GI complaints in a pre-conversion survey. The great-
est improvement after converting to EC-MPS was observed in 
the GSRS abdominal pain subscale, and forty percent of patients 
EC-MPS converted group, n=175 MMF continued group, n=83
Fig. 5. Overall Treatment Effect (OTE) rating for (A) patient-rated general health-related quality of life (HRQoL) and (B) physician-rated GI symptoms after conversion to EC-MPS 
compared to baseline. EC-MPS converted group significantly improved in patient- and physician-rated OTE compared to MMF continued group (all P<0.001). 
EC-MPS, enteric-coated mycophenolate sodium; MMF, mycophenolate mofetil.
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reported an improvement in OTE scales in terms of HRQoL af-
ter converting from MMF to EC-MPS. 
  In previous trials, converting patients from MMF to EC-MPS 
significantly improved GI symptom burden, patient function-
ing, and well-being in renal transplant recipients (8, 9, 15-17). 
However, those trials did not include MMF control group and 
the study population was screened by physicians only. GI symp-
toms tend to be underestimated by physicians, and patients do 
not disclose such information voluntarily. Thus, physician judg-
ments provided a limited amount of information for evaluating 
patient reported outcomes (18-20). In the present study, all pa-
tients were screened by a simple questionnaire method, and its 
score was used as a criteria for patient grouping. Consequently, 
GSRS scores at the baseline were significantly different between 
the two groups. Therefore, the present study is a more effective 
method of evaluating patient-reported outcomes in terms of 
grouping patients on the basis of their own reported symptoms.
  The GSRS score in EC-MPS-converted group was significant-
ly improved, but it was worsened in MMF continued group. In 
addition, non-significant trend towards deteriorated GIQLI 
score was observed for MMF continued group. These findings 
suggest that patients who received a simultaneous treatment of 
MMF and tacrolimus can experience newly developed GI symp-
toms or a lower HRQoL despite the little presence of GI symp-
toms at the baseline. Thus, further investigation is needed to 
determine whether EC-MPS conversion prevented GI symp-
toms and to improved HRQoL in MMF-treated renal transplant 
patients who did not suffer from GI disorder.
  Diarrhea is a frequent adverse event observed during MMF 
treatment in renal transplant recipients. Conversion to EC-MPS 
conversion provided a great benefit on diarrhea (8, 9, 21). How-
ever, diarrhea subscale did not show the greatest improvement 
after EC-MPS conversion in this study-its beneficial effect was 
relatively small in contrast to previous reports. Although various 
parameters were related to this result, tacrolimus could be one 
of the most significant influences. Because tacrolimus is inde-
pendently associated with diarrhea in renal transplant recipi-
ents, its GI adverse effect could offset the improvement of the 
symptom in EC-MPS conversion (7). In addition, a little change 
in constipation subscale of EC-MPS-converted group is attrib-
uted to tacrolimus, because it is also closely associated with con-
stipation. Therefore, it is recommended that tacrolimus-related 
GI side effects should be considered as one of the causes in pa-
tients’ persistent GI symptom after EC-MPS conversion.
  After comparing the overall baseline GIQLI score between EC-
MPS-converted and MMF-continued groups, it was revealed 
that patients with GI complaints had 12% lower overall GIQLI 
score than those without. As expected, a reduced GI symptom 
burden after EC-MPS conversion significantly increased GI-
specific HRQoL. It is noteworthy that EC-MPS conversion sig-
nificantly improved the overall functioning and well-being of 
patients, as indicated by patient-rated OTE. The impact of con-
verting to EC-MPS on general HRQoL was also supported by 
MMF-continued patients, whose patient-rated OTE remained 
unchanged. These findings suggest that GI related symptom 
and HRQoL are closely associated with general HRQoL in renal 
transplant recipients, and that EC-MPS conversion could be 
one of the methods for improving the overall HRQoL.
  The overall incidence of non-GI adverse events in EC-MPS-
converted group was significantly higher than that of MMF con-
tinued group. However, the incidence of non-GI adverse events 
with a suspected relation to study drug, serious adverse events, 
and discontinuation of study drug were similar between both 
groups. In addition, baseline characteristics in EC-MPS-convert-
ed group showed a greater prevalence of younger and female 
patients, and it might be associated with increment of non-GI 
adverse events. Therefore, greater non-GI adverse events of EC-
MPS-converted group in this trial could not be the barrier for 
EC-MPS conversion. 
  In the present study, placebo effect can not be completely 
ruled out. Because neither investigators nor patients were blind-
ed, EC-MPS conversion might have implied to the patients that 
GI-side effects would be alleviated. However, the significant 
improvements of GSRS and GIQLI score scores were observed 
after EC-MPS conversion, and OTE rated by patients and physi-
cians showed consistent results. These findings suggest that ob-
served improvements cannot be explained solely by the place-
bo effect.
  In conclusion, a conversion from MMF to EC-MPS improves 
GI-related symptom and HRQoL in tacrolimus-treated renal 
transplant recipients with GI burdens. The efficacy and safety 
of EC-MPS conversion helps to optimize patient functioning 
and well-being. Ultimately, these improvements translate into 
an increased medication compliance and adherence, which 
may lead to further improvements in graft survival rates. 
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